Human growth hormone: Difference between revisions
Michal Harel (talk | contribs) No edit summary |
Michal Harel (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
<StructureSection load='1hgu' size='350' side='right' caption='Human growth hormone (PDB entry [[1hgu]])' scene=''> | |||
==Function== | ==Function== | ||
'''Human growth hormone''' (hGH) plays a vital role in growth and development. It is naturally produced by somatotropic cells in the anterior pituitary gland. The [[hormone]] is produced as a 217 amino acid precursor protein. The 26 N-terminal amino acids correspond to a signal peptide, which is essential for hormone secretion. This signal peptide is cleaved during the secretion process to yield the mature, 191 amino acid form of hGH. | '''Human growth hormone''' (hGH) plays a vital role in growth and development. It is naturally produced by somatotropic cells in the anterior pituitary gland. The [[hormone]] is produced as a 217 amino acid precursor protein. The 26 N-terminal amino acids correspond to a signal peptide, which is essential for hormone secretion. This signal peptide is cleaved during the secretion process to yield the mature, 191 amino acid form of hGH. | ||
| Line 135: | Line 135: | ||
Certain medications can also be used in some combination with surgery and radiation. There are two classifications of acromegaly medication treatments. The first reduces HgH release from the pituitary. Somatostatin agonists reduce HgH release in approximately 50 percent of patients. They act by binding to somatostatin receptors, which regulate hormone control. The seemingly low level of success is due to certain tumors being resistant to somatostatin agonists. There are currently two somatostatin agonists on the market. Octreotide is a long acting release medication that needs to be injected about once a month. Lanreotide is a slow release medication that needs to be administered by injection about every other week. The second class of medication is an analog of HgH that competitively binds to HgH receptors, without activating them. Pegvisomant is an HgH analog that blocks the binding of HgH to HgH inhibitors. It is injected daily (Freda, 2002; A.D.A.M. Acromegaly). | Certain medications can also be used in some combination with surgery and radiation. There are two classifications of acromegaly medication treatments. The first reduces HgH release from the pituitary. Somatostatin agonists reduce HgH release in approximately 50 percent of patients. They act by binding to somatostatin receptors, which regulate hormone control. The seemingly low level of success is due to certain tumors being resistant to somatostatin agonists. There are currently two somatostatin agonists on the market. Octreotide is a long acting release medication that needs to be injected about once a month. Lanreotide is a slow release medication that needs to be administered by injection about every other week. The second class of medication is an analog of HgH that competitively binds to HgH receptors, without activating them. Pegvisomant is an HgH analog that blocks the binding of HgH to HgH inhibitors. It is injected daily (Freda, 2002; A.D.A.M. Acromegaly). | ||
</StructureSection> | |||
==3D structures of human growth hormone== | ==3D structures of human growth hormone== | ||